Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 13Uterine Cervical Dysplasia 5Neoplasms 3Precancerous Conditions 2Papillomavirus Infections 2Ovarian Neoplasms 2Uterine Neoplasms 1Papilloma 1Ovarian Diseases 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1HIV Infections 1Fallopian Tube Neoplasms 1Cervical Intraepithelial Neoplasia Grade 2/3 1Carcinoma, Ovarian Epithelial 1Atypical Squamous Cells of the Cervix 1Anus Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 10Cisplatin 9Cetuximab 9Paclitaxel 5Radiotherapy 4Nivolumab 4Fluorouracil 4zalutumumab 3Docetaxel 3Taxes 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Gefitinib 2Cyclophosphamide 2Carboplatin 2temsirolimus 1sintilimab 1poly ICLC 1osimertinib 1fludarabine phosphate 1fludarabine 1enzalutamide 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1abemaciclib 1Vorinostat 1Sorafenib 1Risk Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Papanicolaou Test × Clear all
NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡